The path from theoretical physics to biotech is well-trodden enough now that it barely raises eyebrows. What still raises questions, though, is whether applying physics principles to the messy, biological problem of human aging can actually yield therapies that work.
Gero, a Singapore-based startup doing precisely that, announced $17 million in fresh financing on June 17, bringing its total equity haul to $34 million. The round arrived exactly one week after the company earned a Technology Pioneer designation from the World Economic Forum on June 10—the kind of accolade that looks good on pitch decks but doesn't, in itself, validate science.
What might validate Gero's approach? A pharmaceutical giant willing to write very large checks. Last July, Chugai Pharmaceutical, the Japanese arm of Roche, struck a research and licensing deal with Gero that includes an undisclosed upfront payment and milestone payouts potentially reaching $250 million, plus royalties. That agreement, perhaps more than any award, suggests someone in Basel took the physics pitch seriously.
The latest financing round drew participation from Melnichek Investments, along with a collection of technology entrepreneurs and pharmaceutical executives the company declined to name in detail. No lead investor was specified. The round wasn't formally classified beyond "new financing"—a bit of opacity that's become common in biotech's more cautious fundraising climate.
Separating Signal From Noise in a Hundred Million Lives
Peter Fedichev, Gero's CEO and co-founder, describes the company's work as applying a "physics-driven lens" to drug target identification. It's the kind of phrase that can sound like Silicon Valley buzzword soup, except Fedichev brings over 75 publications in theoretical physics to the claim.
The platform sifts through longitudinal health data spanning more than 100 million records, attempting to tease apart what's genuinely irreversible aging from what might be a treatable disease process masquerading as decline. The goal: find drug targets for age-related conditions that others miss because they're not looking through the right analytical framework.
Fedichev co-founded Gero with Max Kholin, now Chief Corporate Development Officer. Last July, the company added Brian K. Kennedy to its board—a significant get, given Kennedy's stint as president and CEO of the Buck Institute for Research on Aging and his current role as a Distinguished Professor at the National University of Singapore. That's the kind of credibility hire that matters in longevity science, where hype often outpaces evidence.
Chugai isn't Gero's only big pharma partner, though it's certainly the largest bet. Back in January 2023, Pfizer struck a research collaboration with the startup to hunt for targets in fibrotic diseases using Gero's machine learning platform. Terms included an upfront payment and discovery milestones, amounts undisclosed. The deal structure in both cases follows a familiar playbook: let the AI startup do the computationally intensive target discovery, then hand off to traditional drug development machinery.
Capital, Carefully Raised
Gero's funding trajectory tells a story of cautious, steady growth rather than the venture-fueled rocket ship narrative common in AI-driven drug discovery. The company's earlier rounds included $2.2 million in August 2020 and a $6 million extension in October 2023 led by Melnichek (with participation from VitaDAO and EPAM co-founder Leonid Lozner), building toward this latest $17 million round that brings total equity capital to $34 million.
The team remains relatively lean. According to LinkedIn, Gero employs between 11 and 50 people across offices in Singapore and the San Francisco Bay Area. Key hires include Aleksandr Sviridov as COO and Eileen Brandenburger, who leads IP and licensing after previous stints at Exscientia and Recursion—two companies that themselves represent different approaches to the AI-meets-drug-discovery thesis.
Gero's scientific credibility rests partly on peer-reviewed work in journals like Nature Communications, where the team has published research on longitudinal blood markers, resilience loss, and theoretical limits of human lifespan. In 2025, the company launched something called ProtoBind-Diff, which it bills as a structure-free AI foundation model for designing small molecules directly from protein sequences. Whether that's a genuine advance or incremental tooling remains to be seen.
Context Matters
The $17 million round arrives amid continued, if somewhat more measured, enthusiasm for AI-driven drug discovery in 2026. Converge Bio pulled in a $25 million Series A in January, backed by Bessemer and executives from Meta, OpenAI, and Wiz. That same period saw Insilico Medicine announce a partnership with Eli Lilly valued at up to $2.75 billion—the kind of number that keeps investors interested even as other corners of biotech struggle.
What separates Gero from the pack, at least in theory, is the physics angle. Most AI drug discovery platforms lean heavily on chemistry, structural biology, or brute-force machine learning across existing compound libraries. Gero's bet is that borrowing analytical tools from physics—particularly those designed to find patterns in noisy, complex systems—can reveal aging mechanisms invisible to traditional biological approaches.
Whether that bet pays off clinically is another question entirely. Drug development is littered with elegant theories that produced nothing useful in patients. For now, though, Gero has something concrete: multiple pharmaceutical partners willing to fund the experiment, and fresh capital to keep the platform running while those collaborations mature.
The company says the new funds will advance its preclinical pipeline and expand its partnership roster. Translation: more target discovery work, more pharma conversations, and perhaps eventually, the thing that actually matters—a drug candidate that makes it into human trials and doesn't fail.
Until then, Gero remains what most AI drug discovery companies are at this stage: a promising platform with impressive partners and unanswered clinical questions. The physics may be sound. The biology, as always, will be the final arbiter.
